https://www.medrxiv.org/content/10.1101/2021.08.06.21261707v...
If they had advertised 42% effectiveness rating when it was first launched they'd have probably gone back to the drawing board. (This is what Pfizer did recently with a second version that was aimed specifically at Delta but didn't fare any better than the first version.)